Methods of restoring cognitive ability using non-peptidic compounds

ABSTRACT

Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ 1-42  monomers.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a method of enhancing cognitive function in a patient who has diminished cognitive function due to ADDL neurotoxicity by administering a non-peptidic compound having a molecular weight of less than 1000.

2. State of the Art

Alzheimer's disease (AD) is a fatal progressive dementia that has no cure at present. Although the molecular basis of the disease is not established, considerable evidence now implicates neurotoxins derived from amyloid beta (Aβ) peptides and in particular the 42-amino acid amyloid beta peptide (Aβ₁₋₄₂). Aβ is an amphipathic peptide, the abundance of which is increased by gene mutations and risk factors linked to AD. Fibrils formed from Aβ constitute the cores of amyloid senile plaques, which are hallmarks of AD brain. Analogous fibrils generated in vitro are lethal to cultured brain neurons. These findings provided the central rationale for the original amyloid cascade hypothesis, a theory in which memory loss was proposed to be the consequence of neuron death caused by fibrillar Aβ (Hardy and Higgins (1992) Science 256:184-185).

Despite its strong experimental support and intuitive appeal, the original amyloid cascade hypothesis has proven inconsistent with key observations, including the poor correlation between dementia and amyloid senile plaque burden (Katzman (1988) Ann. Neurol. 23(2):138-144). Using a transgenic mouse model of AD, two surprising findings were obtained when the mice were treated with monoclonal antibodies against Aβ: (1) vaccinated mice showed reversal of memory loss, with recovery evident in 24 hours; and (2) cognitive benefits of vaccination accrued despite no change in senile plaque levels (Dodart et al. (2002) Nat. Neurosci 5:452-457; Kotilinek et al. (2002) J. Neurosci. 22:6331-6335). Such findings are not consistent with a mechanism for memory loss dependent on neuron death caused by amyloid fibrils.

Salient flaws in the original amyloid cascade hypothesis have been eliminated by an updated amyloid cascade hypothesis that incorporates a role for additional neurologically active molecules formed by Aβ self-assembly. These molecules are amyloid β-derived diffusible ligands (ADDLs), which assemble from Aβ₁₋₄₂ at low concentrations (Lambert et al. (1998) Proc. Natl. Acad. Sci. USA 95:6448-6453). Essentially the missing links in the original amyloid cascade hypothesis, ADDLs rapidly inhibit long term potentiation (Lambert et al. (1998) Proc. Natl. Acad. Sci. USA 95:6448-6453; Walsh et al. (2002) Nature 416: 535-539; Wang et al. (2002) Brain Res. 924:133-140), a classic experimental paradigm for memory and synaptic plasticity. In the updated Aβ cascade hypothesis memory loss stems from synapse failure, prior to neuron death, with failure being caused by ADDLs, not fibrils (Hardy and Selkoe (2002) Science 297:353-356). ADDLs occur in brain tissue and are strikingly elevated in AD brain tissue compared to age matched controls (Kayed et al. (2002) Science 300:486-489; Gong et al. (2003) Proc. Natl. Acad. Sci. USA 100:10417-10422) and in AD transgenic mice models (Kotilinek et al. (2002) J. Neurosci. 22:6331-6335; Chang et al. (2003) J. Mol. Neurosci. 20:305-313).

A simplistic mechanistic approach to this theory can be illustrated as follows:

where formation of ADDLs is a separate pathway from formation of amyloid senile plaque both of which are in equilibrium with monomeric Aβ₁₋₄₂.

Further experiments have shown important neurological properties of ADDLs. ADDLs were shown to have selective toxicity to hippocampal CA1 neurons compared with CA3 neurons, and the complete absence of toxicity towards cerebellar neurons (Kim et al. (2003) FASEB J. 17:118-120). Ventricular injection of Aβ₁₋₄₂ oligomers into wild-type rats resulted in rapid, compromised behavioral models with complete recovery occurring within 24 hours (Cleary et al. (2005) Nat. Neurosci. 8:79-84) and these deficits are attributed to higher order oligomers, specifically 12-mer oligomers (Lesne et al. (2006) Nature 440:352-357). ADDL binding to neurons occurs with high specificity and is localized to post-synaptic receptors on a subset of hippocampal neurons (Lacor et al. (2004) J. Neurosci. 24:10191-10200). This triggers the rapid and persistent up-regulation of the immediate early gene product arc, translation of which is activity dependent at polyribosomes localized to subsets of dendritic spines (Steward et al. (1998) Neuron 21:741-751; Guzowski et al. (2000) J. Neurosci. 20:3993-4001). More recently, ADDLs have been implicated as upstream activators of tau phosphorylation and have been shown to interfere with animal behavior at femtomolar levels (Matsubara et al. (2004) Neurobiol. Aging 25:833-841).

The reversibility of memory loss in mouse models, coupled with the neurological properties of ADDLs and their presence in an AD brain, provides strong support for the hypothesis that AD is a disease of ADDL-induced synaptic failure (Lambert et al. (1998) Proc. Natl. Acad. Sci. USA 95:6448-6453; Klein et al. (2001) Trends Neuroscis. 24:219-220; Selkoe (2002) Science 298:789-791).

The use of antibodies specific to ADDLs is a powerful way to modulate the equilibrium between monomeric ASβ₁₋₄₂ and ADDLs thereby providing treatment for disease conditions mediated by ADDLs. However, antibody delivery is typically limited to injectable solutions which pose patient compliance issues as well as the presence of an attending clinician. Small molecules that modulate this equilibrium, deliverable by non-injectable means such as oral delivery, transdermal delivery, pulmonary delivery, nasal delivery, etc. would be particularly beneficial.

A number of small molecules developed originally as amyloid fibril blockers are purported to possess Aβ oligomer assembly blocking properties. Some of these compounds include Alzhemd™ (Gervais (2004) Neuirobiol. Aging 25:S11-12), Clioquinol (Ritchie et al. (2003) Arch. Neurol. 60:1685-1691), substituted β-cyclodextrins (Yu et al. (2002) J. Mol. Neurosci. 19:51-55), trehalose (Lui (2005) Neurobiol. Disease 20:74-81), simple amino, carbonyl, and nitro substituted phenols (De Felice et al. (2001) FASEB J. March 20; De Felice et al. (2004) FASEB J. 18:1366-1372), Curcumin (Yang et al. (2005) J. Biol. Chem. 280(7):5892-5901), cyclohexanehexol analogs (McLaurin et al. (2006) Nature Med. 12:801-808), spirosterols (Lecanu et al.(2004) Steroids 69:1-16) and tricyclic pyrones (Maeqawa et al. (2006) J. Neurochem. 98:57-67). Two of these compounds, Alzhemd™ and Clioquinol, have progressed into clinical trials.

Alzhemed™ (3-amino-1-propanesulfonic acid), a so-called “GAG mimetic,” is proposed to reduce soluble and insoluble amyloid levels by binding to Aβ monomer, although no experimental details have appeared to confirm the proposed mode of action. Alzhemed™ has recently completed a 20 month open-label extension of a Phase II trial, and there are reports of slowed cognitive decline in some patients with mild AD, however, no efficacy was observed during the blinded phase of the study (Gervais (2004) Neuirobiol. Aging 25:S11-12).

The second compound in a phase II clinical trial, Clioquinol, was shown to stabilize the patients' cognitive ability compared to untreated patients and showed lower Aβ₁₋₄₂ levels in their plasma (Ritchie et al. (2003) Arch. Neurol. 60:1685-1691). However, a toxic impurity (a di-iodo form of Clioquinol) made during production has resulted in the study being halted and Clioquinol being replaced with an analog termed PBT2 (Blennow et al. (2006) Lancet 368:387-403).

Lastly, an unidentified compound or compounds from an extract of ginko biloba leaves was reported to lower the levels of Aβ₁₋₄₂ trimers and tetramers and increase the levels of high molecular weight polymers in a dose dependent manner (Yao et al. (2001) Brain Res. 889:181-190). Dose dependent protection against Aβ oligomer induced toxicity to PC-12 cells was also reported.

Of the compounds reported to block Aβ assembly or bind to Aβ₁₋₄₂ monomer, few appear to have high therapeutic potential. Given its very simple structure and hydrophilic properties, it is highly unlikely that Alzhemed™ has high and selective affinity for Aβ₁₋₄₂ monomer. Any effect that Alzhemed™ has on Aβ aggregation or disaggregation is likely attributable its interaction with ionic residues near the N-terminus of Aβ₁₋₄₂. The cyclodextrins do not have either lead-like or drug-like properties that would recommend them for development (Oprea et al. (2001) J. Chem. Inf. Comput. Sci. 41:1308-1315; Vieth et al. (2004) J. Med. Chem. 47:224-232), and the phenols of De Felice contain aldehyde and nitro functionalities that are often considered reactive and excluded from screening libraries (Walters and Namchuk (2003) Nat. Rev. 2:259-266). A number of molecules containing the phenol functionality have been reported as “frequent hitters” in screening libraries (Roche et al. (2002) J. Med. Chem. 45:137-142). Thus, further evaluation of the activity and selectivity of the phenols of De Felice is needed to confirm that these compounds are valid hits. Some compounds with a steroidal backbone have been reported to be promiscuous inhibitors due to an unexpected self aggregation process (McGovern et al. (2002) J. Med. Chem. 45:1712-1722), which may explain the ambiguous spirosterol results. Finally, the active ingredient in the ginko biloba extract is unknown. Thus, most of the purported Aβ assembly blockers would not be considered compounds for therapeutic development.

Notwithstanding these putative results and as noted above, binding assays indicate that these compounds are, at best, moderate antagonists to ADDL formation.

Accordingly, it would be particularly beneficial to provide for small molecules which provide enhanced inhibition, regulation, and/or modulation of ADDL formation to improve cognitive function.

SUMMARY OF THE INVENTION

This invention is directed to the discovery that soluble, globular, non-fibrillar, neurotoxic Aβ₁₋₄₂ (ADDL) formation can be antagonized by substantially pure non-peptidic compounds having a molecular weight of less than 1500, preferably less than 1000 which compounds antagonize ADDL formation at levels higher than those previously achievable. By antagonizing the ADDL formation, cognitive function is improved. This invention is further directed to the discovery of numerous scaffolds which exhibit this enhanced antagonism evidencing that it is not scaffold dependent.

One embodiment of the invention is directed to a method of enhancing cognitive function in a patient who has diminished cognitive function due to ADDL neurotoxicity. The method comprises administering to the patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

(a) having a molecular weight of less than 1000;

(b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and

(c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In some embodiments of the invention, the diminished cognitive function in a patient is due to the patient suffering from or at risk of suffering from a disease associated with the formation of and/or activity of ADDLs. In other embodiments, the disease is selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke and mild cognitive impairment.

In other embodiments of the invention, the diminished cognitive function in a patient is due to the patient suffering from or at risk of suffering from a disease associated with insoluble amyloid fibrils, senile plaques, and/or tangles. Alternatively, the diminished cognitive function in a patient is due to the patient suffering from or at risk from suffering from a disease associated with over-expression of Aβ₁₋₄₂ protein. In some embodiments, the disease is selected from the group consisting of focal ischemia associated dementia and neuronal degeneration.

In another embodiment, the invention is directed to a method of inhibiting, regulating and or modulating the binding of neurotoxic ADDLs to spines and/or synapses of a neuronal cell. The method comprises contacting said neuronal cell with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

(a) having a molecular weight of less than 1000;

(b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and

(c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In yet another embodiment, the invention is directed to a method of inhibiting, regulating and/or modulating the long term potentiation of neuronal cells. The method comprises contacting said cells with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

(a) having a molecular weight of less than 1000;

(b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and

(c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In another embodiment, the invention is directed to a method of treating a patient suffering from diminished cognitive function due to the patient suffering from or at risk of suffering from a disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia and neuronal degeneration. The method comprises administering to said patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

(a) having a molecular weight of less than 1000;

(b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and

(c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In one embodiment of the invention, the substantially pure non-peptidic compound is administered in an amount of from about 0.05 milligrams to 1000 milligrams, one or more times per day. In another embodiment of the invention, the compound is administered in a pharmaceutical composition, further comprising a phannaceutically acceptable excipient.

In some embodiments, the compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 5 μM, or 2 μM, or 1 μM or less in the assay of Example 1.

The invention is also directed to a composition for enhancing cognitive function in a patient who has diminished cognitive function due to ADDL neurotoxicity, wherein the composition comprises a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

(a) having a molecular weight of less than 1000;

(b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and

(c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

The composition can further comprises a pharmaceutically acceptable excipient.

The present invention also relates to a method a manufacturing a medicament comprising the compound as set forth in the embodiments in this section.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows representative dose dependent assembly inhibition of compounds described herein using FRET analysis. The results of Test Compound A assayed at concentrations between 0.05 to 3 μM are shown as well as the results of Test Compound B assayed at a concentration of 30 μM. The positive and negative controls are also shown. The X axes indicates time in minutes, where as the Y axes indicates the relative fluorescence units (RFU) X 10³ measured by the FRET assay of Example 1.

FIG. 2 shows representative dose dependent assembly inhibition of the putative amyloid fibril blocker compound Alzhemed™ (Neurochem) tested in the FRET assay described herein. The positive and negative controls are also shown. The X axes indicates time in minutes, where as the Y axes indicates the relative fluorescence units (RFU) X 10³ measured by the FRET assay of Example 1.

DETAILED DESCRIPTION OF THE INVENTION A. Methods of the Invention

Before the methods are described, it is to be understood that the invention is not limited to the particular methodologies, protocols, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe particular embodiments of the present invention, and is in no way intended to limit the scope of the present invention as set forth in the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

The definitions used herein are limited to the application of small molecules as they relate to ADDL aggregation or oligomerization and diseases mediated by such.

This invention is directed to the discovery that the formation of soluble, oligomeric, globular, non-fibrillar, neurotoxic Aβ₁₋₄₂ peptides (ADDL) can be antagonized by substantially pure non-peptidic compounds having a molecular weight of less than 1500, preferably less than 1000. The compounds antagonize ADDL formation at levels higher than those previously achievable. A further description of the embodiments relating to antagonizing ADDL formation may be found in PCT application no. PCT/US2007/______, filed on Jul. 12, 2007, titled “Methods of Modifying Amyloid β Oligomers Using Non-Peptidic Compounds,” Attorney Docket No. 089265-1400, which is hereby incorporated by reference in its entirety.

Without being limited by any theory, it is believed that the administration of an therapeutically effective amount of one or more of the compounds described herein will interact with key assembly motifs within the Aβ₁₋₄₂ monomers or within critical motifs on the Aβ₁₋₄₂ oligomers. This interaction, in turn, will prevent formation of neurotoxic ADDLs or the activity of such ligands. The disruption of the ADDLs or the activity of such ligands will protect long term potentiation of neuronal cells thereby obviating and/or reversing the neurotoxicity associated with ADDLs. In addition, this interaction does not interfere with the formation of Aβ senile plaques.

The invention is directed to the enhancing cognitive function in a patient who has diminished function. The term “cognitive function” refers to the intellectual process by which one becomes aware of, perceives, or comprehends ideas. Cognitive function embraces the quality of knowing, which includes all aspects of perception; recognition; conception; sensing; thinking; reasoning; remembering and imagining.

The term “diminished cognitive function” refers to memory loss, mental slowing, intellectual decline and/or amnesia. Memory loss may be characterized as the difficulty or failure for immediate or delayed recall. Mental slowing is the difficulty in processing or completing previously learned tasks in a timely manner or in processing new information quickly. Intellectual decline is defined as a loss of information, or an inability to utilize information previously possessed or utilized by a person. Amnesia is an extreme loss of cognitive ability which results in partial or total inability to recall past experiences and impaired or total loss of the ability to speak or write. Diminished cognitive function may be caused by a number of disease conditions which are more thoroughly discussed below.

Methods of assessing cognitive function include, but are not limited to, standardized instruments for example Folstein Mini-Mental State Examination; Modified Mini-Mental State Exam; Middlesex Elderly Assessment of Mental State; Short Portable Mental Status Questionnaire; Alzheimer's Disease Assessment Scale; Clock Drawing Test; Clinical Dementia Rating; Neuropsychiatric Inventory or any similarly designed test. Using the above listed tests, a skilled clinician would be able to assess the level of diminished cognitive function of a patient or enhanced cognitive function following treatment. Additionally, informal observations and interactions of individuals to a patient can also be used to assess cognitive function and include, but are not limited to, family members, friends, formal care givers such as nurses, and individuals who have previous intimate knowledge of the patient.

Mechanical measure of the neurons and neuronal tissue may also be used to assess cognitive function including, but not limited to, Computed Tomography (CT); Computed Axial Tomography (CAT); Magnetic Resonance Imaging (MRI); Functional Magnetic Resonance Imaging (fMRI); Positron Emission Tomography (PET): Single Photon Emission Computed Tomography (SPECT); Diffuse Optical Imaging (DOI); Diffuse Optical Tomography (DOT) or any similarly designed instrumentation.

The term “non-peptidic compound” refers to a compound, examples of which are described herein, which are not composed of peptides and/or proteins. It is understood that the presence of 1 to 10, or 1 to 5, or 1 to 2 amino acid residues attached to the compound scaffolds disclosed herein do not render such scaffolds peptidic provided that the molecular weight of the compound is less than 1500, preferably less than 1000, and the amino acid residues do not possess any antigen binding function and further provided that the scaffold itself in the absence of the amino acid residues possesses inhibition of ADDL formation as set forth in Example 1 herein. In a preferred embodiment, the non-peptidic compounds described herein contain no amino acid residues derived from one of the 20 naturally occurring amino acids.

The term “peptides” and “proteins” refer to high molecular weight compounds having a plurality of amino acid residues bound through amido (—C(O)—NR—) bonds. The amino acid residues are typically derived from one of the 20 naturally occurring amino acids.

The compounds described herein are useful in a method for inhibiting, regulating and/or modulating assembly of neurotoxic ADDLs either in vitro or in vivo. The term “ADDL” is conventionally defined as amyloid beta-derived diffusable ligands which have the following characteristics: soluble, oligomeric, globular, non-fibrillar, neurotoxic Aβ₁₋₄₂ peptides.

The term “neurotoxicity” refers to the toxic effect of ADDLs on neuronal cells either in vitro and/or in vivo. ADDLs bind to specific neuronal receptors triggering aberrant neuronal signaling, which compromises long term potentiation and causes memory deficits. Thus, ADDLs alter the function of the neuronal cell in such a manner that, while still viable, the neuron does not properly function. Such altered functionality is referred to herein as “neuronal dysfunction,” which is a subclass of neurotoxicity. Persistent ADDL signaling causes aberrant transcription and the progressive loss of synapses, and very long term persistent ADDL signaling and accumulated structural pathology leads to eventual neuron death and gross brain dystrophy.

The term “soluble” means the ability for a given substance, the solute (an example in the instant invention is the Aβ₁₋₄₂ oligomer) to dissolve in a solvent. Within the context of the instant invention, soluble Aβ oligomers are capable of being fractionated by centrifugation.

The term “oligomeric” means a protein complex of a finite number of monomer subunits. In the context of the invention, oligomers are referred to as trimers, low-n-mers, dodecamers (12-mers), and large-n-multimers composed of Aβ₁₋₄₂ peptides. The term “oligomeric” does not include senile amyloid plaques.

The term “globular” means a large soluble protein complex, which is to be distinguished from fibrils and amyloid plaques. Preferably, the globular structure ranges in size from 4 nanometers (nm) to about 12 nm, preferably, from about 4.7 to about 11 nm, which can be observed upon atomic force microscope analysis (AFM) of supernatant fractions of Aβ₁₋₄₂ soluble oligomer preparations as described in U.S. Pat. No. 6,218,506.

The term “non-fibrillar” means the Aβ₁₋₄₂ peptides and oligomeric complexes that are not aligned in a morphologically distinct pattern known as amyloid protofibrils or amyloid fibrils.

The term “substantially pure” is defined as substantially free of impurities, such as less than 20% impurities. In one embodiment, a compound is substantially pure if it contains less than 10% impurities and, in another embodiment, if it contains less than 1% impurities.

As mentioned above, diminished cognitive function may be caused by a number of diseases. The terms “disease,” “disorder,” and “condition” are used inclusively and refer to any condition mediated at least in part by ADDLs. In the context of this invention the disease may be associated with insoluble amyloid fibrils, senile plaques, neurofibrillary tangles, and/or the over-expression of amyloid β₁₋₄₂ protein. Examples include, but are not limited to, Alzheimer's disease, Down's Syndrome, mild cognitive impairment, stroke, focal ischemia associated dementia, and neuronal degeneration. Patients amenable to treatment include individuals at risk of disease but not exhibiting symptoms, as well as patients presently exhibiting symptoms. Therefore, the compounds described herein can be administered prophylactically to the general population without the need for any assessment of the risk of the patient.

The term “tangles” means the neurofibrillary tangles formed inside of degenerating neurons by bundling of paired helical filaments, which assemble from hyperphosphorylated forms of the microtubule-associated protein know as tau.

The term “amyloid fibrils” means protein aggregates sharing specific structural traits. Histopathological techniques generally identify the structures by apple-green birefringence when stained with Congo red and seen under polarized light.

In one aspect of the invention, the compounds of the invention, when administered can inhibit, regulate and/or modulate the long term potentiation of neuronal cells. The phrase “long term potentiation” is an increase in the strength of a chemical synapse that last from minutes to several days. It is known to be one of the major mechanisms by which memories are formed and stored in the brain.

A “neuronal cell” or “neuron” is a cell that transmits and processes signals in the brain or other parts of the nervous system. Additionally, a neuronal cell, as used in the invention, can be isolated from animal brain tissue and grown in tissue culture. The isolated cells can be comprised of an established neuronal cell line selected from for example, but are not limited to, MC65; HCN-2; SH-SY5Y; SK-N-AS; SK-N-FI; SK-N-DZ; H19-7/IGF-IR; QNR/D; QNR/K2; C8-D30; C8-S; C8-D1A; OLGA-PH-J/92; Daoy; RSC96; SW10; RT4-D6P2T; RN33B; PC-12; DBRTG-05MG; C8-B4; SK-N-SH; B35; R3[33-10ras3]; Neuro-2A; and HCN-1A or any genetic, chemical, and/or biochemical modified variants thereof. The isolated cells can also be comprised of primary cells and/or astrocytes isolated from neuronal tissues selected from, for example, but are not limited to, the hippocampus; cerebellum; cortex; hypothalamus; mid-brain; spinal cord; striatum; frontal lobe; temporal lobe; parietal lobe; occipital lobe and any genetic, chemical, and/or biochemical modified variants thereof. The isolated, cultured animal cell can be comprised of a neural stem cell or any differentiated, genetic, chemical, and/or biochemical modified variants thereof.

As used herein, the term “neuronal tissue” refers to any portion of the central nervous system including, but not limited to, the brain or spinal cord. Neuronal tissue can be composed of, at least in part, neuronal cells.

The methods are especially useful for individuals who have a known genetic risk of Alzheimer's disease. Such individuals include those having relatives who have been diagnosed with the disease and those whose risk is determined by analysis of genetic or biochemical markers. Genetic markers of risk for Alzheimer's disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 referred to as the Hardy and Swedish mutations respectively. Other markers of risk are mutations in the presenilin genes, PS1 and PS2, and ApoE4, family history of Alzheimer's Disease, hypercholesterolemia or atherosclerosis. Individuals presently suffering from Alzheimer's disease can be recognized from characteristic dementia, as well as the presence of risk factors described above. In addition, a number of diagnostic test are available for identifying individuals who have Alzheimer's disease. These include measurement of CSF tau and Aβ₁₋₄₂ levels. Individuals suffering from Alzheimer's disease can also be diagnosed by ADRDA criteria or the method disclosed herein.

In asymptomatic patients, treatment can begin at any age (e.g., 10, 20, 30 years of age). Usually, however, it is not necessary to begin treatment until a patient reaches 40, 50, 60, or 70 years of age. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying for the presence of ADDLs over time.

The term “patient” refers to animals, including mammals, humans, and non-human mammals. In certain embodiments, a patient is an animal, particularly an animal selected from a mammalian species including rat, rabbit, bovine, ovine, porcine, canine, feline, murine, equine, and primate, particularly human.

“Treating” or “treatment” of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms: or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

The term “suffering” as it related to the term “treatment” refers to a patient or individual who has been diagnosed with or is predisposed to a disease. A patient may also be referred to being “at risk of suffering” from a disease. This patient has not yet developed characteristic disease pathology, however are know to be predispose to the disease due to family history, being genetically predispose to developing the disease, or diagnosed with a disease or disorder that predisposes them to developing the disease to be treated.

In addition to Alzheimer's disease, several other disease are know to be associated with Aβ₁₋₄₂ formation including, but are not limited to, Down's Syndrome, stroke and mild cognitive impairment. It is conceivable that similar to Alzheimer's disease, treatment of patients suffering from or at risk of suffering from these diseases is possible due to the parallel mechanisms of the diseases.

The term “senile plaque” or “senile plaque formation” refers to the extracellular deposit of amyloid in the gray matter of the brain. The deposits are associated with degenerative neural structures. It is understood that senile plaque is different from and distinguished over ADDLs.

Similarly, over-expression of Aβ₁₋₄₂ is associated with focal ischemia associated dementia and neuronal degeneration. Over-expression of Aβ₁₋₄₂ is believed to result in accumulation of ADDLs, thereby inducing neurotoxicity. Treating a patient suffering from or at risk of suffering from one of these diseases by administration of one or more of the compounds described herein will ameliorate the neurotoxicity of over-expressed Aβ₁₋₄₂.

In therapeutic applications, a pharmaceutical composition containing one or more compounds described herein is administered to a patient suspected of, or already suffering from such a disease associated with the accumulation of ADDLs, wherein said compounds are administered in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease (biochemical, histological and/or behavioral), including its complication and intermediate pathological phenotypes in development of the disease. In prophylactic applications, a pharmaceutical composition containing one or more compounds described herein is administered to a patient susceptible to, or otherwise at risk of, a disease associated with the accumulation of ADDLs, wherein said compounds are administered in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease. This includes biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease.

The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the patient to be treated all of which is within the skill of the attending clinician. It is contemplated that a therapeutically effective amount of one or more of the compounds described herein will alter ADDL formation (including inhibiting or reversing formation of ADDLs) in the patient as compared to binding of ADDLs in the absence of treatment. As such, impairment of long term potentiation and subsequent memory formation is decreased. A therapeutically effective amount is distinguishable from an amount having a biological effect (a “biologically effective amount”). A compound of the present invention may have one or more biological effects in vitro or even in vivo, such as reduction in ADDL formation to some extent. A biological effect, however, may not result in any clinically measurable therapeutically effect as described above as determined by methods within the skill of the attending clinician.

In some methods, administration of the compound reduces or eliminates mild cognitive impairment in patients that have not yet developed characteristic Alzheimer's pathology. In particular embodiments, a therapeutically effective amount intends to indicate the amount of one or more compounds described herein administered or delivered to the patient which is most likely to result in the desired response to treatment.

An “effective amount” is an amount of one or more of the compounds described herein which treats the ADDL mediated disease. Preferably, the compounds of this invention will decrease ADDL formation either in vitro or in vivo by at least 10%, 25%, 40%, 60%, 80%, 90% or 95% as compared to control.

B. Compounds

The compounds useful in the methods described herein are substantially pure, non-peptidic and have a molecular weight of less than 1000. In one embodiment, the compounds useful in the methods of the invention preferably contain one or more and any combination of the following characteristics: (1) low or sub-micromolar potency when tested in the FRET assay described herein; (2) non-aggregating; (3) little or no neuronal toxicity when administered to a patient; (4) favorable solubility in an aqueous environment; (5) chemically tractable; (6) dose dependent characteristics; (7) reversibly bind to the Aβ protein; (8) capable of amyloid β monomer binding; (9) capable of binding soluble amyloid β oligomers.

In one embodiment of the invention, the compounds useful for treating patients are suitable for oral delivery. In this embodiment, the compound are compliant with Lipinski's rule-of-five which provides a criteria to evaluate drug likeness. The rule states that, in general, an orally active drug has: no more than 5 hydrogen bond donors (OH and NH groups); no more than 10 hydrogen bond acceptors (notably N and O); a molecular weight under 500 g/mol; and a partition coefficient log P less than 5.

1. Compound Selection

A preferred method of selecting compounds for their use in the methods of the invention involves assaying the compounds with Fluorescence Resonance Energy Transfer (FRET). FRET has been used to measure, detect, identify, assay, analyze, and characterize various interactions and processes in biological systems (see e.g., Mitra et al. (1996) Gene 173:13-17; De Angelis (1999) Physiol. Genomics. 21:93-99; Latif and Graves (2000) Thyroid 10(5):407-412; Rye (2001) Methods 24(3):278-288; Kenworthy (2001) Methods 24(3):289-296; Periasamy (2001) J. Biomed. Opt. 6(3):287-291; Truong and Ikura (2001) Curr. Opin. Struct. Biol. 11(5):573-578; Zhang et al. (2002) Nat. Rev. Mol. Cell. Biol. 3(12):906-918; Sitte and Freissmuth (2003) Eur. J. Pharmacol. 479:229-236; Milligan (2004) Eur. J. Pharm. Sci. 21(4):397-405; Herman et al. (2004) Methods Mol. Biol. 261:351-370; Roda et al. (2004) Trends Biotechnol. 22(6):295-303; Wallrabe and Periasamy (2005) Curr. Opin. Biotechnol. 16(1):19-27; Milligan and Bouvier (2005) FEBS J. 272(12):2914-2915; references in any of the foregoing; and the like).

FRET methods, protocols, techniques, assays, and the like are described generally and specifically in a number of patents and patent applications, including: U.S. Pat. No. 6,908,769; U.S. Pat. No. 6,824,990; U.S. Pat. No. 6,762,280; U.S. Pat. No. 6,689,574; U.S. Pat. No. 6,661,909; U.S. Pat. No. 6,642,001; U.S. Pat. No. 6,639,078; U.S. Pat. No. 6,472,156; U.S. Pat. No. 6,456,734; U.S. Pat. No. 6,376,257; U.S. Pat. No. 6,348,322; U.S. Pat. No. 6,323,039; U.S. Pat. No. 6,291,201; U.S. Pat. No. 6,280,981; U.S. Pat. No. 5,914,245; U.S. Pat. No. 5,661,035; references in any of the foregoing; and the like.

Similarly, fluorescence polarization (FP) has also been used to measure, detect, identify, assay, analyze, and characterize various interactions and processes in biological systems (see e.g., Lundblad et al. (1996) Mol. Endocrinol. 10(6):607-612; Nasir and Jolley (1999) Comb. Chem. High Throughput Screen. 2(4):177-190; Park and Raines (2004) Methods Mol. Biol. 261:161-166; references in any of the foregoing; and the like).

Fluorescence polarization (FP) methods, protocols, techniques, assays, and the like are described generally and specifically in a number of patents and patent applications, including: U.S. Pat. No. 6,794,158; U.S. Pat. No. 6,632,613; U.S. Pat. Nos. 6,630,295; 6,596,546; U.S. Pat. Nos. 6,569,628; 6,555,326; U.S. Pat. No. 6,511,815; U.S. Pat. No. 6,448,018; U.S. Pat. No. 6,432,632; U.S. Pat. No. 6,331,392; U.S. Pat. No. 6,326,142; U.S. Pat. No. 6,284,544; U.S. Pat. No. 6,207,397; U.S. Pat. No. 6,171,807; U.S. Pat. No. 6,066,505; U.S. Pat. No. 5,976,820; U.S. Pat. No. 5,804,395; U.S. Pat. No. 5,756,292; U.S. Pat. No. 5,445,935; U.S. Pat. No. 5,427,960; U.S. Pat. No. 5,407,834; U.S. Pat. No. 5,391,740; U.S. Pat. No. 5,315,015; U.S. Pat. No. 5,206,179; U.S. Pat. No. 5,070,025; U.S. Pat. No. 5,066,426; U.S. Pat. No. 4,952,691; U.S. Pat. No. 4,863,876; U.S. Pat. No. 4,751,190; U.S. Pat. No. 4,681,859; U.S. Pat. No. 4,668,640; U.S. Pat. No. 4,614,823; U.S. Pat. No. 4,585,862; U.S. Pat. No. 4,510,251; U.S. Pat. No. 4,476,229; U.S. Pat. No. 4,429,230; U.S. Pat. No. 4,420,568; U.S. Pat. No. 4,203,670; references in any of the foregoing; and the like.

FRET and FP have been used in the field of amyloid research (see e.g., U.S. Pat. No. 6,927,401; U.S. Pat. No. 6,906,104; U.S. Pat. No. 6,905,827; U.S. Pat. No. 6,881,546; U.S. Pat. No. 6,864,290; U.S. Pat. No. 6,864,103; U.S. Pat. No. 6,858,383; U.S. Pat. No. 6,846,813; U.S. Pat. No. 6,828,106; U.S. Pat. No. ______ U.S. Pat. No. 6,803,188; U.S. Pat No. 6,770,448; U.S. Pat. No. 6,713,276; U.S. Pat. No. 6,600,017; U.S. Pat. No. 6,515,113; U.S. Pat. No. 6,495,664; U.S. Pat. No. 6,323,039; U.S. Pat. No. 6,294,330; U.S. Pat. No. 6,280,981; U.S. Pat. No. 6,197,928; U.S. Pat. No. 5,981,200; Kim and Lee (2004) Biochem. Biophys. Res. Commun. 316(2):393-397; Bacskai et al. (2003) J. Biomed. Opt. 8(3):368-375; Gonnan, P.M. et al. (2003) J. Mol. Biol. 325(4):743-757; Garzon-Rodrequez et al. (1997) J. Biol. Chem. 272(34):21037-21044; Lindgren et al. (2005) Biophys. J. 88(6):4200-4212; Lewis et al. (2004) Neurobiol. Aging 25(9): 1175-1185; Leissring et al. (2003) J. Biol. Chem. 278(39):37314-37320; Taylor et al. (2003) J. Protein Chem. 22(1):31-40; Allsop et al. (2001) Biochem. Soc. Symp. 67:1-14; Allsop et al. (2001) Biochem. Biophys. Res. Commun. 285(1):58-63; Huang et al. (2000) J. Biol. Chem. 275(46):36436-36440; references in any of the foregoing; and the like).

2. Applications of FRET to Compound Discovery

The FRET assay of Example 1 was used on a variety of commercially available compound libraries to assess the specific binding inhibition ADDLs of each compound. Lead compounds were identified and further compound libraries were obtained. In addition, structure activity relationships around lead compounds were conducted leading to still further enhancements in activity.

3. Exemplary Compounds Useful in the Methods of the Invention

Certain examples of compounds useful in this invention are presented below in Table 1 below. It is to be understood that the illustration of these compounds is in no way limiting the invention to the compounds described in these tables and it is therefore contemplated that other compounds are suitable for use in this invention.

Also provided in the table are the compounds IC₅₀ values as tested using the assay described in Example 1. In each case, the compounds recited either were commercially available or their synthesis is described in the Examples of this application. It should also be noted that the following compounds may exhibit stereoisomerism (i.e., E and Z isomers) and the invention contemplates use of either isomer and mixtures thereof.

TABLE 1 Exemplary Compounds No. Compound Structure Compound Name IC₅₀ (μM) Source 1.

2-Hydroxy-benzoic acid [3-oxo-3-(1-methyl-1H-pyrazol-5-yl)-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazide 17.7 deCODE 2.

2-Hydroxy-benzoic acid [3-oxo-3-thiophen-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazide 26.0 deCODE 3.

2-Hydroxy-benzoic acid [3-oxo-3-furan-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazide 13.5 deCODE 4.

N-(2-Methoxy-phenyl)-2-oxo-2-{N′-[3-oxo-3-thiophen-2-yl-1-trifluoromethyl-prop-(Z)-ylidene]-hydrazino}-acetamide 3.9 deCODE 5.

2-{[1-(2-Hydroxy-3-methoxy-phenyl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester 3.5 Aldrich 6.

2-{[1-(2-Hydroxynaphthalen-1-yl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester 4.4 Aldrich 7.

2-{[1-(2-Hydroxyphenyl)-meth-(E)-ylidene-hydrazinooxalyl]-amino}-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester 1.1 Aldrich 8.

2-(3-ethyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide 7.0 ChemDiv 9.

2-(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide 6.4 ChemDiv 10.

2-(5-hydroxy-3-isopropyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide 24.3 ChemDiv 11.

2-(5-hydroxy-3-isobutyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide 3.2 ChemDiv 12.

(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)(2-hydroxyphenyl)methanone 8.5 ChemDiv 13.

N-(4-bromophenyl)-2-(3-ethyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide 17.0 ChemDiv 14.

2-(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide 34.4 ChemDiv 15.

N-(4-bromophenyl)-2-(5-hydroxy-3-propyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide 7.8 ChemDiv 16.

2-(3-butyl-5-hydroxy-5-trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide 38.8 ChemDiv 17.

2-(5-hydroxy-3-isobutyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide 41.3 ChemDiv 18.

N-(4-bromophenyl)-2-(5-hydroxy-3-pentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoacetamide 11.6 ChemDiv 19.

2-(5-hydroxy-3-pentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide 8.7 ChemDiv 20.

2-(5-hydroxy-3-isopentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxo-N-phenethylacetamide 17.0 ChemDiv 21.

2-(5-hydroxy-3-isopentyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide 6.4 ChemDiv 22.

2-(3-hexyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-2-oxoacetamide 8.2 ChemDiv 23.

2-(3-cyclohexyl-5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide 29.1 ChemDiv 24.

(E)-2-hydroxy-N′-((2-hydroxynaphthalen-1-yl)methylene)benzohydrazide 26.8 deCODE 25.

(E)-2-hydroxy-N′-((1-hydroxynaphthalen-2-yl)methylene)benzohydrazide 3.8 deCODE 26.

(E)-N′-(3,5-dibromo-2-hydroxybenzylidene)-2-hydroxybenzohydrazide 5.8 deCODE 27.

(E)-N′-(5-bromo-2-hydroxybenzylidene)-2-hydroxybenzohydrazide 19.3 deCODE

C. Testing and Administration

Effective doses of the compositions of the present invention, for the treatment of the above described diseases vary depending upon may different factors, including means of administration, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but in certain embodiments, a patient is an animal, particularly an animal selected from a mammalian species including rat, rabbit, bovine, ovine, porcine, canine, feline, murine, equine, and primate.

The compounds can be administered on multiple occasions, wherein intervals between single dosages can be daily, weekly, monthly, or yearly. Intervals can also be irregular as indicated by measuring blood levels of Aβ₁₋₄₂ protein or ADDLs, or ADDL complexes in the patient. Alternatively, one or more of the compounds of the invention can be administered as a sustained-release formulation, in which case less frequent administration is required. Dosage and frequency may vary depending on the half-life of the compounds of the invention. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of the disease. Thereafter, the patient can be administered a prophylactic regime.

Administration of a pharmaceutical composition of the compounds described herein can be carried out via a variety of routes including, but are not limited to, oral, topical, pulmonary, rectal, subcutaneous, intradermal, intranasal, intracranial, intramuscular, intraocular, or intra-articular injection and the like. The most typical route of administration is oral, although other routes can be equally effective.

One or more compounds described herein can optionally be administered in combination with other biological or chemical agents that are at least partly effective in treatment of a Aβ₁₋₄₂ associated disease. An example of such an agent is, but are not limited to, Aβ₁₋₄₂ targeted antibodies as described in International Application Nos.: WO 2003/253673; WO 2006/014478, U.S. Pat. No. 2,489,195, U.S. Publication No. 2007-0048312, and U.S. application Ser. No. 11/571,532, which are incorporated herein by reference.

The compounds described herein may be administered to a patient in an amount sufficient to inhibit, regulate and/or modulate the formation of neurotoxic ADDLs or the activity of such ligands in said patient. A skilled clinician would be able to readily ascertain appropriate amounts of the compounds described here to effectively inhibit, regulate and/or modulate the formation of neurotoxic ADDLs or the activity of such ligands in said patient. Contemplated amounts of the compounds described herein include for example, but are not limited to, from about 0.05 to 2000 mg/m2/day of one compound or more than one compound.

As noted above, the compounds described herein may be administered for example, but are not limited to, orally, topically, pulmonaryly, rectally, subcutaneously, intradermally, intranasally, intracranially, intramuscularly, intraocularly, or intra-arterially and the like. The carrier or excipient or excipient mixture can be a solvent or a dispersive medium containing for example, but are not limited to, various polar or non-polar solvents, suitable mixtures thereof, or oils. As used herein “carrier” or “excipient” means a pharmaceutically acceptable carrier or excipient and includes any and all solvents, dispersive agents or media, coating(s), antimicrobial agents, iso/hypo/hypertonic agents, absorption-modifying agents, and the like. The use of such substances and the agents for pharmaceutically active substances is well known in the art. Moreover, other or supplementary active ingredients can also be incorporated into the final composition.

Diseases which are treated by the methods described herein include Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia and neuronal degeneration.

D. Pharmaceutical Formulations and Routes of Administration

When employed as pharmaceuticals, the compounds of this invention are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, topical, pulmonary, rectal, subcutaneous, intradermal, intranasal, intracranial, intramuscular, intraocular, or intra-articular injection. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds described herein associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. The excipient employed is typically an excipient suitable for administration to patient. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

Administration of therapeutic agents by intravenous formulation is well known in the pharmaceutical industry. An intravenous formulation should possess certain qualities aside from being just a composition in which the therapeutic agent is soluble. For example, the formulation should promote the overall stability of the active ingredient(s), also, the manufacture of the formulation should be cost effective. All of these factors ultimately determine the overall success and usefulness of an intravenous formulation.

Other accessory additives that may be included in pharmaceutical formulations of compounds of the present invention as follow: solvents: ethanol, glycerol, propylene glycol; stabilizers: ethylene diamine tetraacetic acid (EDTA), citric acid; antimicrobial preservatives: benzyl alcohol, methyl paraben, propyl paraben; buffering agents: citric acid/sodium citrate, potassium hydrogen tartrate, sodium hydrogen tartrate, acetic acid/sodium acetate, maleic acid/sodium maleate, sodium hydrogen phthalate, phosphoric acid/potassium dihydrogen phosphate, phosphoric acid/disodium hydrogen phosphate; and tonicity modifiers: sodium chloride, mannitol, dextrose.

The presence of a buffer may be necessary to maintain the aqueous pH in the range of from about 4 to about 8 and more preferably in a range of from about 4 to about 6. The buffer system is generally a mixture of a weak acid and a soluble salt thereof, e.g., sodium citrate/citric acid; or the monocation or dication salt of a dibasic acid, e.g., potassium hydrogen tartrate; sodium hydrogen tartrate, phosphoric acid/potassium dihydrogen phosphate, and phosphoric acid/disodium hydrogen phosphate.

The amount of buffer system used is dependent on (1) the desired pH; and (2) the amount of drug. Generally, the amount of buffer used is in a 0.5:1 to 50:1 mole ratio of buffer:drug (where the moles of buffer are taken as the combined moles of the buffer ingredients, e.g., sodium citrate and citric acid) of formulation to maintain a pH in the range of 4 to 8 and generally, a 1:1 to 10:1 mole ratio of buffer (combined) to drug present is used.

One useful buffer in the invention is sodium citrate/citric acid in the range of 5 to 50 mg per mL of sodium citrate to 1 to 15 mg per mL of citric acid, sufficient to maintain an aqueous pH of 4-6 of the composition.

The buffer agent may also be present to prevent the precipitation of the drug through soluble metal complex formation with dissolved metal ions, e.g., Ca, Mg, Fe, Al, Ba, which may leach out of glass containers or rubber stoppers or be present in ordinary tap water. The agent may act as a competitive complexing agent with the drug and produce a soluble metal complex leading to the presence of undesirable particulates.

In addition, the presence of an agent, e.g., sodium chloride in an amount of about of 1-8 mg/mL, to adjust the tonicity to the same value of human blood may be required to avoid the swelling or shrinkage of erythrocytes upon administration of the intravenous formulation leading to undesirable side effects such as nausea or diarrhea and possibly to associated blood disorders. In general, the tonicity of the formulation matches that of human blood which is in the range of 282 to 288 mOsm/kg, and in general is 285 mOsm/kg, which is equivalent to the osmotic pressure corresponding to a 0.9% solution of sodium chloride.

The intravenous formulation can be administered by direct intravenous injection, i.v. bolus, or can be administered by infusion by addition to an appropriate infusion solution such as 0.9% sodium chloride injection or other compatible infusion solution.

The compositions can be formulated in an oral unit dosage form. The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for a patient, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.05 to about 2000 mg of the active ingredient of the present invention.

The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

The following formulation examples illustrate the contemplated pharmaceutical compositions of the present invention.

FORMULATION EXAMPLE 1

Hard gelatin capsules containing the following ingredients are prepared:

Ingredient Quantity (mg/capsule) Active Ingredient 30.0 Starch 305.0 Magnesium stearate 5.0

The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

FORMULATION EXAMPLE 2

A tablet formula is prepared using the ingredients below:

Ingredient Quantity (mg/tablet) Active Ingredient 25.0 Cellulose, microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0

The components are blended and compressed to form tablets, each weighing 240 mg.

FORMULATION EXAMPLE 3

A dry powder inhaler formulation is prepared containing the following components:

Ingredient Weight % Active Ingredient 5 Lactose 95

The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

FORMULATION EXAMPLE 4

Tablets, each containing 30 mg of active ingredient, are prepared as follows:

Ingredient Quantity (mg/tablet) Active Ingredient 30.0 mg  Starch 45.0 mg  Microcrystalline cellulose 35.0 mg  Polyvinylpyrrolidone 4.0 mg (as 10% solution in sterile water) Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1.0 mg

The active ingredient, starch, and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50° C. to 60° C. and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.

FORMULATION EXAMPLE 5

Capsules, each containing 40 mg of medicament are made as follows:

Ingredient Quantity (mg/capsule) Active Ingredient 40.0 mg Starch 109.0 mg  Magnesium stearate  1.0 mg Total 150.0 mg

The active ingredient, starch and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

FORMULATION EXAMPLE 6

Suppositories, each containing 25 mg of active ingredient are made as follows:

Ingredient Amount Active Ingredient    25 mg Saturated fatty acid glycerides to 2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.

FORMULATION EXAMPLE 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

Ingredient Amount Active Ingredient 50.0 mg Xanthan gum 4.0 mg Sodium carboxymethyl cellulose (11%) Microcrystalline cellulose (89%) 50.0 mg Sucrose 1.75 g Sodium benzoate 10.0 mg Flavor and Color q.s. Purified water to 5.0 mL

The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

FORMULATION EXAMPLE 8

Quantity Ingredient (mg/capsule) Active Ingredient  15.0 mg Starch 407.0 mg Magnesium stearate  3.0 mg Total 425.0 mg

The active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425.0 mg quantities.

FORMULATION EXAMPLE 9

A subcutaneous formulation may be prepared as follows:

Ingredient Quantity Active Ingredient 5.0 mg Corn Oil 1.0 mL

FORMULATION EXAMPLE 10

An intravenous formulation may be prepared as follows:

Ingredient Quantity Active Ingredient  250 mg Isotonic saline 1000 mL

Another formulation employed in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. No. 5,023,252, issued Jun. 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Pat. No. 5,011,472, which is herein incorporated by reference.

Indirect techniques, usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxyl, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions, which can transiently open the blood-brain barrier.

Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, Pa., 17th ed. (1985).

As noted above, the compounds described herein are suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the in vivo serum half-life of the administered compound, the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.

In prophylactic applications, compositions are administered to a patient at risk of developing AD (determined for example by genetic screening or familial trait) in an amount sufficient to inhibit the onset of symptoms of the disease. An amount adequate to accomplish this is defined as “prophylactically effective dose.” Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the age, weight and general condition of the patient, and the like.

As noted above, the compounds administered to a patient are in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 and 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius.

EXAMPLES

The invention is further understood by reference to the following examples, which are intended to be purely exemplary of the invention. The present invention is not limited in scope, by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only. Any methods that are functionally equivalent are within the scope of the invention. Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.

In these examples and elsewhere, abbreviations have the following meanings:

μl = Microliter g = Gram h = Hour Hz = Hertz M = Molar mg = Milligram min = Minute mL = Milliliter mM = Millimolar mm = Millimeter mmol = Millimolar mol = Moles MS = Mass Spectroscopy N = Normal nm = Nanometer μM = Micromolar DMSO = dimethylsulfoxide

EXAMPLE 1 FRET Assay

Fluorescence (or Förster) Resonance Energy Transfer (FRET) is a distance-dependent, non-radiative transfer of energy in which the de-excitation of one fluorophore (donor) is coupled to excitation of another fluorophore (acceptor). FRET occurs if (1) the quantum of energy emitted by a donor fluorophore corresponds to an acceptor fluorophore's excitation energy, (2) the orientations of donor and acceptor transition dipoles are nearly parallel and (3) the donor fluorescent emission spectrum overlaps the acceptor absorption spectrum.

In this assay, Aβ₁₋₄₂ oligomer formation is monitored by FRET using N-terminal conjugates of fluorescein-Aβ₁₋₄₂ as both the donor and acceptor fluorophore (fluorescein-fluorescein R_(o)˜45 Å). Aβ₁₋₄₂ monomers assembling into oligomeric species results in a decrease of fluorescence as the fluorescein labeled Aβ₁₋₄₂ peptides become proximal to each other and FRET efficiency increases. Inhibition of Aβ₁₋₄₂ assembly is observed as the absence or attenuation of fluorescein quenching.

FRET and FP assays are performed in 384-well Coming Non-Binding Surface, black, opaque microtiter plates, and the assay buffer consists of 50 mM MOPS-Tris (pH 8.0) with 100 mM MgCl₂. The assay volume, containing 0.2 μM FITC-Aβ(1-42) and 0.8 μM Aβ(1-42), is 50 μl and the temperature is 37° C. ADDL assembly is monitored on a Tecan GENios Pro plate reader, exciting at a wavelength of 485 nm and detecting emission at a wavelength of 515 nm. Kinetic traces are collected by recording fluorescence intensity and polarization readings every five minutes over about three to about a six-hour time course. Negative control reactions, which do not appreciably assemble into ADDLs during this time, lack MgCl₂ but contain all other buffer and peptide components. Positive control reactions contain all buffer components in the absence of added small molecule or antibody reagents. To test for ADDL assembly inhibition, the non-peptidic compound was incubated with the peptide mixture at six concentrations from about 30 82 M decreasing to about 0.05 μM.

Using the above described assay with the conditions of: 1 mM Aβ₁₋₄₂ total monomer; 100 mM MgCl₂; and Test Compound A ranging from 0.05 to 3 mM, Test Compound A shows dose dependent inhibition of Aβ₁₋₄₂ oligomer assembly as shown in FIG. 1. Test Compound A appears as compound 7 in Table 1. Additionally, Test Compound B assayed at a concentration of 30 μM shows only partial assembly inhibition at very high concentrations (FIG. 1). Examples of other compounds having a molecular weight of less than 1000 and requisite activity as tested in this assay are found in Table 1.

EXAMPLE 2 Comparative Example of Putative Aβ Assembly Blocker

Using the FRET assay described above, several compounds originally developed as amyloid fibril blockers were tested for blocking of Aβ₁₋₄₂ monomer assembly into Aβ oligomers. The compounds tested include, Alzhemed™ (Neurochem), scyllo-inositol also know as AZD-103 (Ellipsis), SP-235 (Samaritan), benzofurans (GE), 9-acridinones (Warner-Lambert), cyclodextrins (University of Illinois, Chicago), RS-406 (Sankyo), Clioquinol (Prana), and Curcumin (UCLA/UCI). Standard FRET assay conditions described in Example 1 were used. The inability of the compound Alzhemed to inhibit Aβ₁₋₄₂ monomer assembly into Aβ oligomers is shown in FIG. 2. These results are representative of all the compounds listed above, which were originally developed as amyloid fibril blockers.

EXAMPLE 3 Alternating Lever Cyclic Ratio Rat Model Introduction

Preparations of Aβ₁₋₄₂ ADDLs and a potential therapeutic compounds under the Alternating Lever Cyclic Ratio (ALCR) rat model of AD were tested. This highly sensitive model has been able to detect cognitive deficits due to direct injection of cell-derived Aβ oligomers into rat brain. In this study, a direct injection of ADDLs made from synthetic Aβ₁₋₄₂ and a putative therapeutic compound under the ALCR procedure were tested.

The ALCR test has proven to be much more sensitive than previously published methods for measuring drug effects on cognitive function. In this task, rats must learn a complex sequence of lever-pressing requirements in order to earn food reinforcement in a two-lever experimental chamber. Subjects must alternate between two levers by switching to the other lever after pressing the first lever enough to get food reward. The exact number of presses required for each food reward changes, first increasing from 2 responses per food pellet up to 56 presses per food pellet, then decreasing back to 2 responses per pellet. Intermediate values were based on the quadratic function, x²−x. One cycle was an entire ascending and descending sequence of these lever press requirements (e.g., 2, 6, 12, 20, 30, 42, 56, 56, 42, 30, 20, 12, 6, and 2 presses per food reward). Six such full cycles were presented during each daily session. Errors were scored when the subject perseveres on a lever after pressing enough to get the food reward, i.e., does not alternate (a Perseveration Error), or when a subject switches levers before completing the response requirement on that lever (an Approach Error).

Materials and Methods

Synthetic Aβ₁₋₄₂ powder was dissolved in 1,1,1,3,3,3 hexafluorisopropanol (HFIP) to afford a solution of Aβ₁₋₄₂ in HFIP of about 1 mM and allowed to incubate at ambient temperature for about 1 h. The resulting solution was chilled on ice for about 5-10 min, then aliquoted into eppendorf tubes to provide about 50 μl of solution per tube. The tubes were then placed in a chemical fume hood and allowed to stand overnight to allow the HFIP to evaporate under a slow stream of nitrogen. To removed final traces of HFIP, the tubes were subjected to two SpeedVac cycles of 15 min at room temperature and about 15 to 25 in Hg of vacuum. The resulting films of monomerized Aβ₁₋₄₂ peptide were stored over desiccant at −80° C. until used.

A tube of monomerized Aβ₁₋₄₂ peptide was warmed to room temperature and the Aβ₁₋₄₂ peptide was dissolved in anhydrous DMSO to afford a peptide stock DMSO solution containing about 10 μM to about 100 μM Aβ₁₋₄₂ peptide in DMSO.

2 μl of a 20 mM stock solution of test compound in anhydrous DMSO is added to 998 μl of neural basal media (phenol red free, Gibco 12348-017) to give a compound neural basal media solution containing 40 μM of test compound in neural basal media.

For the Aβ₁₋₄₂ peptide only treatment, peptide stock DMSO solution is added to 37° C. neural basal to obtain the requisite Aβ₁₋₄₂ peptide monomer concentration, provided that the maximum concentration of DMSO is 1% or less, and the tube is vortexed for 30 to 60 seconds, spun down briefly in a microfuge and incubated at 37° C. for 15 min prior to the start of injections.

For the Aβ₁₋₄₂ peptide plus test compound treatment, peptide stock DMSO solution is added to 37° C. compound neural basal media solution to obtain the requisite Aβ₁₋₄₂ peptide monomer concentration, provided that the maximum concentration of DMSO is 1% or less, and the tube is vortexed for 30 to 36 seconds, spun down briefly in a microfuge and incubated at 37° C. for 15 min prior to the start of injections.

For control injections, compound neural basal media solution is incubated at 37° C. for 15 min prior to the start of injections.

Rats: Rats were trained under ALCR until their error rates were stable. Once the rats were placed upon the final ALCR procedure, training sessions were conducted 7 days each week until the end of the study.

Surgery: All rats received a single 28 ga cannula, which was permanently affixed to the skull, and aimed at the lateral ventricle. Half the rats received cannula in the right ventricle and half received cannula in the left ventricle. Rats were allowed 5 days to recover from surgery before training resumed.

Injection of Test material and ALCR Testing: Test were conducted about every fourth day. Animals received a 20 μl injection of control, peptide, or peptide plus compound solutions via the implanted cannula over about 3 to 4 minutes. Animals were tested about 3 hours following injection.

Error Rate Analysis: All error rates under will be compared to baseline error rates consisting of at least 3 non-treatment days temporally contiguous to the injection. Student's T test of statistical inference was used for analysis of effects.

Results

A significantly increased Perseveration Error rate was found between baseline error rates and error rates produced by the requisite concentration of Aβ₁₋₄₂ ADDLs (Table 2). Test Compound C did not increase error rates when given alone. When Test Compound C was combined with the requisite concentration of Aβ₁₋₄₂ ADDLs, the compound eliminated the increase in Perseveration Errors. Thus, Test Compound C rescued errors produced by the requisite concentration of Aβ₁₋₄₂ ADDLs. Test Compound C appears as compound 24 in Table 1.

TABLE 2 ALCR Error Rate Approach Perseveration Errors Errors Injectate Mean SEM p value Mean SEM p value Aβ₁₋₄₂ ADDLs 1.02 0.07 NS 1.33 0.16 0.045 Test Compound C 0.96 0.07 NS 0.95 0.15 NS Aβ₁₋₄₂ ADDLs + Test 1.00 0.08 NS 0.92 0.10 NS Compound C Base line error rate equalized to 1.00. NS represents no statistically significant difference.

From the foregoing description, various modifications and changes in the compositions and methods will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein. 

1. A method of enhancing cognitive function in a patient who has diminished cognitive function due to ADDL neurotoxicity which method comprises administering to the patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by: (a) having a molecular weight of less than 1000; (b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and (c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.
 2. The method of claim 1, wherein the diminished cognitive function in a patient is due to suffering from or at risk of suffering from a disease associated with formation of and/or activity of ADDLs.
 3. The method of claim 2, wherein the disease is selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke and mild cognitive impairment.
 4. The method of claim 1, wherein the substantially pure non-peptidic compound is administered in an amount of from about 0.05 milligrams to 1000 milligrams, one or more times per day.
 5. The method of claim 4, wherein the compound is administered in a pharmaceutical composition, further comprising a pharmaceutically acceptable excipient.
 6. The method of claim 1, wherein the diminished cognitive function in a patient is due to a disease associated with insoluble amyloid fibrils, senile plaques, and/or tangles.
 7. The method of claim 1, wherein the diminished cognitive function in a patient is due to a disease associated with over-expression of Aβ₁₋₄₂ protein.
 8. The method of claim 7, wherein disease is selected from the group consisting of focal ischemia associated dementia and neuronal degeneration.
 9. A method of inhibiting, regulating and or modulating the binding of neurotoxic ADDLs to spines and/or synapses of a neuronal cell which comprises contacting said neuronal cell with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by: (a) having a molecular weight of less than 1000; (b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and (c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.
 10. A method of inhibiting, regulating and/or modulating the long term potentiation of neuronal cells which method comprises contacting said cells with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by: (a) having a molecular weight of less than 1000; (b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and (c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.
 11. A method of treating a patient suffering from diminished cognitive function due to suffering from or at risk of suffering from a disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia and neuronal degeneration, the method comprising administering to said patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by: (a) having a molecular weight of less than 1000; (b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and (c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.
 12. The method of claim 11, wherein the substantially pure non-peptidic compound is administered in an amount of from about 0.05 milligram to about 1000 milligram, one or more times per day.
 13. The method of claim 12, wherein the compound is administered in a pharmaceutical composition, further comprising a pharmaceutically acceptable excipient.
 14. The method of claims 1, 9, 10, or 11, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an lC₅₀ of about 5 μM or less in the assay of Example
 1. 15. The method of claim 14, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 2 μM or less in the assay of Example
 1. 16. The method of claim 9 or 10, wherein said neuronal cell are isolated from animal brain tissue and grown in tissue culture.
 17. A composition for enhancing cognitive function in a patient who has diminished cognitive function due to ADDL neurotoxicity, wherein the composition comprises a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by: (a) having a molecular weight of less than 1000; (b) being an antagonist against formation of neurotoxic ADDLs from Aβ₁₋₄₂ monomers; and (c) exhibiting IC₅₀ of about 55 μM or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.
 18. The composition of claim 17, wherein the composition further comprises a pharmaceutically acceptable excipient. 